Bovine Respiratory Disease remains a multi-billion dollar challenge for the global cattle industry. While PCR testing identifies the presence of M. bovis DNA, it fails to capture the animal's actual immune response. The study, published in Frontiers in Veterinary Science, marks a significant shift by proving that antibody monitoring can be effectively performed using simple nasopharyngeal swabs rather than invasive blood draws.

Led by Dr. Robert Valeris-Chacin of the Department of Veterinary Pathobiology, the team analyzed archived samples from 100 crossbreed feedlot steers. The results were robust, yielding 97.6% overall accuracy, 100% sensitivity, and 95.2% specificity. Beyond precision, the assay demonstrated high inter-operator reproducibility, suggesting the platform is reliable for laboratory environments where consistency is critical. Dr. Valeris-Chacin noted the ease of interpretation, even when dealing with complex, archived biological samples.

This research is the fourth independent validation of the Pictor platform since 2025. While the current findings are limited to this specific cohort of feedlot steers, the data provides a strong proof-of-concept for the technology. Pictor Holdings, headquartered in Carlsbad, California, continues to position the platform as a scalable solution for livestock health monitoring, though the company notes the system is currently intended for research use only.